Cutaneous adverse reactions to the new oral antiviral drugs against SARS‐CoV‐2

Correia, Madalena Pupo; Fernandes, Sónia; Filipe, Paulo

doi:10.1111/ced.15281

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first report of EM that showed a positive outcome in a patient with COVID-19, who was treated with nirmatrelvir/ritonavir. Previous studies have reported EM after COVID-19 and lopinavir/ritonavir administration 9 . Likewise, EM associated with COVID-19 has been described in the medical literature, both in patients aged <30 years and in those aged >55 years 7 .…”

Section: Discussionmentioning

confidence: 95%

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

Tavares-Júnior

FILHO

Galvão

2023

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration. An 81-year-old woman presented with fever and dyspnea. Laboratory investigations showed positive coronavirus disease (COVID-19) based on polymerase chain reaction assay, and she received a 5-day regimen of nirmatrelvir/ritonavir. We observed development of EM after this treatment and initiated prednisone (1 mg/kg) therapy, which led to rapid improvement. Our study is the first to report EM in a patient with COVID-19, who received nirmatrelvir/ ritonavir and showed a favorable response.

show abstract

Section: Discussionmentioning

confidence: 95%

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

Tavares-Júnior

FILHO

Galvão

2023

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Our brief report describes the development of EM after completion of Paxlovid™ for COVID-19 infection. To date, there have been several adverse cutaneous manifestations of this drug that have been documented, including maculopapular rash, hyperkeratosis, hyperhidrosis, pruritus, skin edema, skin exfoliation, and alopecia [ 8 ]. However, there have been very few reports documenting the development of EM related to the use of this medication, especially due to drug interactions [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Erythema Multiforme in an HIV+ Patient on Highly Active Antiretroviral Therapy After Starting Paxlovid (Nirmatrelvir-Ritonivir)

Cáceres,

Bono,

Kothari

2024

Cureus

View full text Add to dashboard Cite

In this report, we present a case of a woman currently on HIV antiretroviral therapy who presented with oral mucosal and cutaneous skin lesions with a target-like appearance following completion of a five-day course of Paxlovid™ for symptomatic COVID-19 infection. The patient was treated with intravenous steroids and oral antihistamines with mild improvement. However, she returned in one week with worsening skin lesions. The biopsy and infectious workup were non-contributory. It was determined that the patient had developed erythema multiforme (EM), secondary to Paxlovid™.

show abstract

“…Antiviral drugs, particularly those used in the context of COVID-19 treatments (Nobari et al, 2020) like Paxlovid™ and Lagevrio® have been associated with dermatological reactions (Pupo-Correia et al, 2022). Some of the documented effects of antiviral drugs owing to gene variations in patients are depicted in Table 1.…”

Section: Antiviralsmentioning

confidence: 99%

Pharmacogenomics as a Tool in Addressing Genetic VariationDependent Adverse Drug Reactions

Anunobi

2024

dujopas

View full text Add to dashboard Cite

Adverse drug reactions (ADRs) are a cause of discontinuing drug development and withdrawal from market, as well as a very common source of morbidity and mortality. Genetic variables may be the primary predictor of drug response for certain medications, but they are estimated to account for 15– 30% of the variability in drug response. Many factors can contribute to adverse drug reactions, including genetics and drug targeting/delivery. Genetic markers, such as single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes, drug targets, and human leukocyte antigen (HLA) genotypes, have been associated with an increased risk of ADRs. Pharmacogenomics is the study of the genetic variation in the way that different people react to different pharmaceuticals, including variations in the risk of adverse drug reactions, dose requirements, and efficacy. The implementation of genetic data for predicting responses to medications and ADRs is becoming a reality in clinical practice, offering the potential to reduce the incidence of ADRs and improve patient outcomes. As pharmacogenomic research continues to advance, it holds great promise for enhancing drug safety and efficacy, ultimately leading to more tailored and effective therapeutic interventions.

show abstract

Cutaneous adverse reactions to the new oral antiviral drugs against SARS‐CoV‐2

Cited by 5 publications

References 6 publications

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

Erythema Multiforme in an HIV+ Patient on Highly Active Antiretroviral Therapy After Starting Paxlovid (Nirmatrelvir-Ritonivir)

Pharmacogenomics as a Tool in Addressing Genetic VariationDependent Adverse Drug Reactions

Contact Info

Product

Resources

About